← All trials
NCT02260375
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2014
- Primary completion
- Oct 1, 2024
- Completion date
- Oct 1, 2025
- First posted
- —
- Last posted
- —
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- A.O. Ospedale Papa Giovanni XXIIILead sponsor
- University of BresciaOverall official - principal investigator
- Laboratorio G. Lanzani, BergamoOverall official - principal investigator
- University of BresciaSponsor investigator
- University of BresciaStudy chair
- Mario Negri InstituteCollaborator
- Vita-Salute University of Milano. ItalyStudy director
- University of BolognaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.